Unlock Next Generation

T cell therapy

We arm your cell to fight untreatable diseases

Executive Members

We are led by experts in both business & medical area,

with comprehansive experience to develop novel T cell therapy in clinical treatment

Armed-T cell platform

Provide solution for Untreatable cancer

CytoArm - Next generation T cell therapy

Armed-T cell dosage and schedule in clinical practice

One aphresis for multiple treatments
One cycle 4 treatments
30 min infusion
Without long-term hospitalization

We aimed

We armed

We cured

• Cell therapy startup company established in 2020
• Lead by world-classed drugs and management teams
• Broad multi-nation technology patent portfolio with continuous new patents


• The first candidate is ready to initiate an investigator-initiated clinical trial in EGFR expressed Kras, Braf, and Nras mutations in end-stage untreatable metastatic colorectal cancer
• Three more candidates are under development for various untreatable diseases



2019 & 2020 National Innovation Awards

We’re excited to announce that CytoArm won the 2019 & 2020 National Innovation Awards!
Our Armed-T platform focused on untreat....


CytoArm Intellectual Property

  • CytoArm’s Armed-T has obtained patents including:
  • Korea (1)
  • Taiwan (2)
  • Australia (1)
  • Japan (1....

Contact Us

One step forward, 3 times faster
Let's aim to the future